<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109160</url>
  </required_header>
  <id_info>
    <org_study_id>AZI002</org_study_id>
    <secondary_id>2010-018724-16</secondary_id>
    <nct_id>NCT01109160</nct_id>
  </id_info>
  <brief_title>Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation</brief_title>
  <acronym>AZI002</acronym>
  <official_title>A Prospective, Open-label Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fund for Scientific Research, Flanders, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the role of azithromycin treatment for lymphocytic
      bronchitis/bronchiolitis after lung transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphocytic bronchitis/bronchiolitis is one of the major risk factors for development of
      chronic rejection/BOS after lung transplantation. There is currently no established treatment
      available for this condition. There is now mounting evidence that IL-17 producing lymphocytes
      (TH17) not only participate in chronic allograft rejection/BOS, but are also present within
      the airway wall during lymphocytic bronchiolitis and that IL-17 mRNA-levels in
      bronchoalveolar lavage fluid of these patients are upregulated. As such, TH17 may account for
      the increased BAL neutrophilia seen in these patients, as IL-17 may be responsible for
      driving IL-8 secretion (a neutrophil-attracting chemokine) from various cell types in the
      airways. Since azithromycin has previously been shown to reduce both IL-17 induced IL-8
      production by human airway smooth muscle cells 'in vitro' and bronchoalveolar IL-8/neutrophil
      levels in LTx recipients with established BOS, we believe that azithromycin has great
      potential for treating lymphocytic bronchi(oli)tis by attenuating this
      TH17/IL-17/IL-8-mediated airway inflammation, possibly even halting the subsequent
      development of chronic rejection/BOS after lung transplantation. In this study, histologic,
      spirometric, bronchoalveolar an radiologic features will be investigated in patients treated
      with confirmed lymphocytic bronchitis/bronchiolitis treated with azithromycin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histology on bronchial and/or transbronchial biopsies</measure>
    <time_frame>after 3 months of treatment</time_frame>
    <description>Evolution of lymphocytic airway inflammation after 3 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary function (FEV1)</measure>
    <time_frame>after 3 months of treatment</time_frame>
    <description>Evolution of FEV1 after 3 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bronchoalveolar cellularity and protein levels (IL-8, IL-17)</measure>
    <time_frame>after 3 months of treatment</time_frame>
    <description>Evolution of bronchoalveolar cellularity and protein levels (IL-8, IL-17) after 3 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiologic features</measure>
    <time_frame>after 3 months of treatment</time_frame>
    <description>Evolution of radiologic features (e.g. tree-in-bud, consolidation, bronchiectasis, air trapping, etc.) on chest X-ray or HRCT after 3 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function (FEV1)</measure>
    <time_frame>after 6 months of treatment</time_frame>
    <description>Evolution of FEV1 after 6 months of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Lymphocytic Bronchi(Oli)Tis Post-lung Transplantation</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Add-on of study-drug (azithromycin) to 'standard of care': 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin Dihydrate</intervention_name>
    <description>Add-on of study-drug (azithromycin) to 'standard of care' at diagnosis of lymphocytic bronchi(oli)tis.
Study-drug regime: 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).</description>
    <arm_group_label>Azithromycin</arm_group_label>
    <other_name>Azithromycin 250 mg, ZTM250, Zitromax TM (ATC J01FA10)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Adult (age at least 18 years old at moment of transplantation)

          -  Able to take oral medication

          -  Histologic diagnosis of lymphocytic bronchiolitis or bronchitis ('grade B') without
             concurrent acute cellular allograft rejection 'grade A' â‰¥2

        Exclusion Criteria:

          -  Severe suture problems (e.g. airway stenosis) requiring lasering or stenting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert M Verleden, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KULeuven and UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Vanaudenaerde BM, De Vleeschauwer SI, Vos R, Meyts I, Bullens DM, Reynders V, Wuyts WA, Van Raemdonck DE, Dupont LJ, Verleden GM. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant. 2008 Sep;8(9):1911-20. doi: 10.1111/j.1600-6143.2008.02321.x.</citation>
    <PMID>18786233</PMID>
  </reference>
  <reference>
    <citation>Vanaudenaerde BM, Wuyts WA, Geudens N, Dupont LJ, Schoofs K, Smeets S, Van Raemdonck DE, Verleden GM. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant. 2007 Jan;7(1):76-82. Epub 2006 Oct 25.</citation>
    <PMID>17061983</PMID>
  </reference>
  <reference>
    <citation>Vanaudenaerde BM, Dupont LJ, Wuyts WA, Verbeken EK, Meyts I, Bullens DM, Dilissen E, Luyts L, Van Raemdonck DE, Verleden GM. The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J. 2006 Apr;27(4):779-87.</citation>
    <PMID>16585086</PMID>
  </reference>
  <reference>
    <citation>Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006 Sep 1;174(5):566-70. Epub 2006 Jun 1.</citation>
    <PMID>16741151</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>July 3, 2013</last_update_submitted>
  <last_update_submitted_qc>July 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>GM. Verleden</investigator_full_name>
    <investigator_title>Medical Director Leuven Lung Transplant Programme</investigator_title>
  </responsible_party>
  <keyword>azithromycin</keyword>
  <keyword>lymphocytic bronchitis or bronchiolitis</keyword>
  <keyword>lung transplantation</keyword>
  <keyword>acute allograft rejection</keyword>
  <keyword>chronic allograft rejection</keyword>
  <keyword>bronchiolitis obliterans syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

